一种亲再生的超分子原药保护并修复实验性结肠炎中的结肠损伤
Kelsey G DeFrates1, Elaine Tong1, Jing Cheng1
1Department of Bioengineering, University of California, Berkeley, Berkeley, CA, 94720, USA.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|January 22, 2024
概括
一种新型的酸酶 (PHD) 抑制剂,DPCA,通过升调缺氧诱导因子一-α (HIF-1α) 来促进肠道再生. 这种通过水凝输送的小分子在炎症性肠病模型中加速愈合并恢复组织结构.
科学领域:
- 胃肠病学 胃肠病学
- 再生医学是一种再生医学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 肠道的愈合对于炎症性肠病 (IBD) 缓解至关重要,但目前的治疗方法没有针对性.
- 缺氧诱导因子一-α (HIF-1α) 在组织修复和再生中起作用.
研究的目的:
- 为了研究一种酸酶 (PHD) 抑制剂DPCA的潜力,以诱导哺乳动物的肠道再生.
- 评估通过自组装水凝输送的DPCA在治疗IBD诱导大肠炎的疗效.
主要方法:
- 开发一种超分子凝,用于持续地皮下输送PEG-DPCA合物.
- 在治疗前和疾病发作后,向患有硫酸 (DSS) 诱导的大肠炎的小鼠给予PEG-DPCA.
- 通过监测体重增加,组织结构和上皮质屏障完整性来评估治疗效果.
主要成果:
- 用PEG-DPCA进行预治疗,可以预防DSS诱导的大肠炎症状和上皮质侵蚀.
- 一次剂量PEG-DPCA在疾病发作后给药,加速体重增加和完全恢复结肠组织结构.
- DPCA治疗上调了HIF-1α的表达,这表明了一种涉及表皮细胞转移到介质酶细胞的机制,用于屏障恢复.
结论:
- 通过水凝输送的DPCA显示出促进IBD肠道再生和愈合的巨大潜力.
- 作为IBD的辅助或独立疗法,DPCA显示出有前途的潜力,解决了未满足的愈需求.
- 对DPCA在IBD中的恢复能力进行进一步的研究是有必要的.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
142
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
142
Prodrugs
2.6K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
2.6K
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
490
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
490
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
441
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
441


